IP Library Granted Patent US 9,980,985
Granted Patent B2
US 9,980,985 · App. 14/473,521 · Granted May 29, 2018

Pharmaceutical coposition of cardiac stem cells and mesenchymal stem cells

Inventors: Joshua Hare (Miami Beach, FL); Konstantinos Chatzistergos (Miami Beach, FL); Alan W. Heldman (Miami, FL)
Assignee: Vestion, Inc.
A61K35/34A61K35/28C12N5/0663A61K2035/124
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,980,985
App. No.
14/473,521
Granted
May 29, 2018
Kind
B2
Abstract

Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.

Claims (12)

1. A pharmaceutical composition comprising mesenchymal stem cells and c-kit + cardiac stem cells and a pharmaceutically acceptable carrier, wherein the carrier is selected from the group consisting of phosphate buffered saline (PBS), culture media, physiological saline and 5% dextrose in water.

2. The pharmaceutical composition of claim 1 , further comprising cardiac tissue.

3. The pharmaceutical composition of claim 1 , wherein composition is a solution with a concentration of 10-40×10 6 mesenchymal stem cells/ml.

4. The pharmaceutical composition of claim of claim 1 , wherein the composition comprises 1 million mesenchymal stem cells.

5. The pharmaceutical composition of claim 1 , wherein the composition is in a unit dosage form of 20-50 μl.

6. The pharmaceutical composition of claim 1 , wherein the composition is suitable for injection.

7. The pharmaceutical composition of claim 1 , wherein the carrier is phosphate buffered saline (PBS).

8. The pharmaceutical composition of claim 7 , wherein the culture media is serum free.

9. The pharmaceutical composition of claim 1 , further comprising a cardiotropic factor.

10. The pharmaceutical composition of claim 1 , wherein the carrier is culture media.

11. The pharmaceutical composition of claim 1 , wherein the carrier is physiological saline.

12. The pharmaceutical composition of claim 1 , wherein the carrier is 5% dextrose in water.

Assignments (4)
CONFIRMATORY LICENSE Recorded Apr 9, 2018
From: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046437/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2017
From: HARE, JOSHUA
To: VESTION, INC.
Reel/Frame 041928/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2017
From: CHATZISTERGOS, KONSTANTINOS
To: VESTION, INC.
Reel/Frame 041928/0481 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2017
From: HELDMAN, ALAN W.
To: VESTION, INC.
Reel/Frame 041928/0565 →
Continuity (5)
Division 12751445 · Mar 31, 2010
Continuation In Part PCTUS2008078379 · Oct 1, 2008
Provisional Application 60976663 · Oct 1, 2007
Provisional Application 61183316 · Jun 2, 2009
Related Publication 20140369976A1 · Dec 18, 2014